XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
OPERATING EXPENSES    
General and administrative $ 1,453us-gaap_GeneralAndAdministrativeExpense $ 1,169us-gaap_GeneralAndAdministrativeExpense
Research and development 3,071us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost 3,124us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Total operating expenses 4,524us-gaap_OperatingExpenses 4,293us-gaap_OperatingExpenses
Interest and other expenses (income), net 43us-gaap_InterestAndOtherIncome (158)us-gaap_InterestAndOtherIncome
Loss from operations before taxes 4,567us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest 4,135us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax benefit (400)us-gaap_IncomeTaxExpenseBenefit (21)us-gaap_IncomeTaxExpenseBenefit
Net Loss 4,167us-gaap_ProfitLoss 4,114us-gaap_ProfitLoss
Less: Net Loss attributable to the noncontrolling interest 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest (193)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net Loss attributable to Capstone Therapeutics Corp. stockholders $ 4,167us-gaap_NetIncomeLoss $ 3,921us-gaap_NetIncomeLoss
Per Share Information:    
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share) $ 0.10us-gaap_EarningsPerShareBasicAndDiluted $ 0.10us-gaap_EarningsPerShareBasicAndDiluted
Basic and diluted shares outstanding (in shares) 40,885us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 40,885us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted